Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?
Fiche publication
Date publication
avril 2023
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges, Pr TRUC Gilles
Tous les auteurs :
Tensaouti F, Desmoulin F, Gilhodes J, Roques M, Ken S, Lotterie JA, Noël G, Truc G, Sunyach MP, Charissoux M, Magné N, Lubrano V, Péran P, Cohen-Jonathan Moyal E, Laprie A
Lien Pubmed
Résumé
All glioblastoma subtypes share the hallmark of aggressive invasion, meaning that it is crucial to identify their different components if we are to ensure effective treatment and improve survival. Proton MR spectroscopic imaging (MRSI) is a noninvasive technique that yields metabolic information and is able to identify pathological tissue with high accuracy. The aim of the present study was to identify clusters of metabolic heterogeneity, using a large MRSI dataset, and determine which of these clusters are predictive of progression-free survival (PFS).
Mots clés
Glioblastoma, MRI spectroscopy, progression-free survival
Référence
Radiother Oncol. 2023 04 4;:109665